

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1-17. (Canceled).

18. (Currently Amended) A method of reducing the weight in-of an overweight subject, said method comprising: administering to an overweight subject a pharmaceutical composition comprising zonisamide, or a pharmaceutically acceptable salt thereof, in an amount effective to reduce the weight in-of said subject, ~~wherein said weight loss is significant and sustained.~~

19. (Previously Presented) The method according to claim 18, wherein said effective amount of zonisamide is in the range of about 50 to about 1000 mg/day.

20. (Previously Presented) The method according to claim 19, wherein said effective amount of zonisamide is in the range of about 100 to about 600 mg/day.

21. (Previously Presented) The method according to claim 18, wherein said overweight subject is an obese subject.

22. (Previously Presented) The method according to claim 18 wherein said pharmaceutical compositions is administered by a route selected from the group consisting of oral, parenteral, topical, injection and rectal administration.

23. (Previously Presented) The method according to claim 22, wherein said pharmaceutical composition is administered orally to said subject.

24. (Previously Presented) The method according to claim 18, wherein said pharmaceutical composition is administered in combination with another therapeutic method commonly used to reduce weight.

25. (Currently Amended) The method according to claim 24, wherein said pharmaceutical composition is administered in combination with a hypocalorie-reduced calorie diet or-exercise increased physical activity.

26. (Previously Presented) The method according to claim 24, wherein said pharmaceutical composition is administered in combination with orlistat, phentermine, sibutramine, topiramate, or sibutramine hydrochloride.

27-34. (Canceled).

35. (Currently Amended) A method of reducing weight in an overweight subject, said method comprising: administering to an overweight subject a pharmaceutical composition comprising zonisamide, or a pharmaceutically acceptable salt thereof, in an amount effective to induce weight loss in said subject, wherein the ~~induction of~~ weight loss is ≥ 5%, or wherein said weight loss continues during the period of administration of said composition comprising zonisamide or a pharmaceutically acceptable salt thereof, sustained during the dosing regimen.

36. (Previously Presented) The method according to claim 35, wherein said effective amount of zonisamide is in the range of about 50 to about 100 mg/day.

37. (Previously Presented) The method according to claim 35, wherein said effective amount of zonisamide is in the range of about 100 to about 600 mg/day.

38. (Previously Presented) The method according to claim 35, wherein said overweight subject is an obese subject.

39. (Previously Presented) The method according to claim 35, wherein said pharmaceutical composition is administered by a route selected from the group consisting of oral, parenteral, topical, injection and rectal administration.

40. (Previously Presented) The method according to claim 39, wherein said pharmaceutical composition is administered orally to said subject.

41. (Previously Presented) The method according to claim 35, wherein said pharmaceutical composition is administered in combination with another therapeutic method commonly used to reduce weight.

42. (Currently Amended) The method according to claim 41, wherein said pharmaceutical composition is administered in combination with a hypocalorie-reduced calorie diet or exercise-increased physical activity.

43. (Previously Presented) The method according to claim 42, wherein said pharmaceutical composition is administered in combination with orlistat, phentermine, sibutramine, topiramate, or sibutramine hydrochloride.

44. (New) A method of treating obesity by reducing the weight of an obese subject, said method comprising: administering to an obese subject an effective amount of a

pharmaceutical composition comprising zonisamide, or a pharmaceutically acceptable salt thereof.

45. (New) The method according to claim 44, wherein said effective amount of zonisamide is in the range of about 50 to about 100 mg/day.

46. (New) The method according to claim 44, wherein said effective amount of zonisamide is in the range of about 100 to about 600 mg/day.

47. (New) The method according to claim 44, wherein said obese subject has a BMI of at least 30 kg/m².

48. (New) The method according to claim 44, wherein said pharmaceutical composition is administered by a route selected from the group consisting of oral, parenteral, topical, injection and rectal administration.

49. (New) The method according to claim 48, wherein said pharmaceutical composition is administered orally to said subject.

50. (New) The method according to claim 44, wherein said pharmaceutical composition is administered in combination with another therapeutic method commonly used to reduce weight.

51. (New) The method according to claim 50, wherein said pharmaceutical composition is administered in combination with a reduced calorie diet or increased physical activity.

52. (New) The method according to claim 51, wherein said pharmaceutical composition is administered in combination with orlistat, phentermine, sibutramine, topiramate, or sibutramine hydrochloride.